174 related articles for article (PubMed ID: 32978326)
1. Structure of the Complex of an Iminopyridinedione Protein Tyrosine Phosphatase 4A3 Phosphatase Inhibitor with Human Serum Albumin.
Czub MP; Boulton AM; Rastelli EJ; Tasker NR; Maskrey TS; Blanco IK; McQueeney KE; Bushweller JH; Minor W; Wipf P; Sharlow ER; Lazo JS
Mol Pharmacol; 2020 Dec; 98(6):648-657. PubMed ID: 32978326
[TBL] [Abstract][Full Text] [Related]
2. Next-Generation Cell-Active Inhibitors of the Undrugged Oncogenic PTP4A3 Phosphatase.
Lazo JS; Blanco IK; Tasker NR; Rastelli EJ; Burnett JC; Garrott SR; Hart DJ; McCloud RL; Hsu KL; Wipf P; Sharlow ER
J Pharmacol Exp Ther; 2019 Dec; 371(3):652-662. PubMed ID: 31601683
[TBL] [Abstract][Full Text] [Related]
3. Credentialing and Pharmacologically Targeting PTP4A3 Phosphatase as a Molecular Target for Ovarian Cancer.
Lazo JS; Sharlow ER; Cornelison R; Hart DJ; Llaneza DC; Mendelson AJ; Rastelli EJ; Tasker NR; Landen CN; Wipf P
Biomolecules; 2021 Jun; 11(7):. PubMed ID: 34209460
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of bifunctional PTP4A3 phosphatase inhibitors activating the ER stress pathway.
Rastelli EJ; Sannino S; Hart DJ; Sharlow ER; Lazo JS; Brodsky JL; Wipf P
Bioorg Med Chem Lett; 2021 Aug; 46():128167. PubMed ID: 34089839
[TBL] [Abstract][Full Text] [Related]
5. Disruption of Ovarian Cancer STAT3 and p38 Signaling with a Small-Molecule Inhibitor of PTP4A3 Phosphatase.
Lazo JS; Isbell KN; Vasa SA; Llaneza DC; Rastelli EJ; Wipf P; Sharlow ER
J Pharmacol Exp Ther; 2023 Mar; 384(3):429-438. PubMed ID: 36627205
[TBL] [Abstract][Full Text] [Related]
6. A chemical genetics approach identifies PTP4A3 as a regulator of colon cancer cell adhesion.
McQueeney KE; Salamoun JM; Ahn JG; Pekic P; Blanco IK; Struckman HL; Sharlow ER; Wipf P; Lazo JS
FASEB J; 2018 Oct; 32(10):5661-5673. PubMed ID: 29746167
[TBL] [Abstract][Full Text] [Related]
7. In-flow photooxygenation of aminothienopyridinones generates iminopyridinedione PTP4A3 phosphatase inhibitors.
Tasker NR; Rastelli EJ; Blanco IK; Burnett JC; Sharlow ER; Lazo JS; Wipf P
Org Biomol Chem; 2019 Feb; 17(9):2448-2466. PubMed ID: 30746541
[TBL] [Abstract][Full Text] [Related]
8. A screen of FDA-approved drugs identifies inhibitors of protein tyrosine phosphatase 4A3 (PTP4A3 or PRL-3).
Rivas DR; Dela Cerna MVC; Smith CN; Sampathi S; Patty BG; Lee D; Blackburn JS
Sci Rep; 2021 May; 11(1):10302. PubMed ID: 33986418
[TBL] [Abstract][Full Text] [Related]
9. Investigational inhibitors of PTP4A3 phosphatase as antineoplastic agents.
Sharlow ER; Wipf P; McQueeney KE; Bakan A; Lazo JS
Expert Opin Investig Drugs; 2014 May; 23(5):661-73. PubMed ID: 24625356
[TBL] [Abstract][Full Text] [Related]
10. Targeting ovarian cancer and endothelium with an allosteric PTP4A3 phosphatase inhibitor.
McQueeney KE; Salamoun JM; Burnett JC; Barabutis N; Pekic P; Lewandowski SL; Llaneza DC; Cornelison R; Bai Y; Zhang ZY; Catravas JD; Landen CN; Wipf P; Lazo JS; Sharlow ER
Oncotarget; 2018 Feb; 9(9):8223-8240. PubMed ID: 29492190
[TBL] [Abstract][Full Text] [Related]
11. Protein-tyrosine phosphatase 4A3 (PTP4A3) promotes vascular endothelial growth factor signaling and enables endothelial cell motility.
Zimmerman MW; McQueeney KE; Isenberg JS; Pitt BR; Wasserloos KA; Homanics GE; Lazo JS
J Biol Chem; 2014 Feb; 289(9):5904-13. PubMed ID: 24403062
[TBL] [Abstract][Full Text] [Related]
12. A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage.
Daouti S; Li WH; Qian H; Huang KS; Holmgren J; Levin W; Reik L; McGady DL; Gillespie P; Perrotta A; Bian H; Reidhaar-Olson JF; Bliss SA; Olivier AR; Sergi JA; Fry D; Danho W; Ritland S; Fotouhi N; Heimbrook D; Niu H
Cancer Res; 2008 Feb; 68(4):1162-9. PubMed ID: 18281492
[TBL] [Abstract][Full Text] [Related]
13. Protein tyrosine phosphatase 4A3 (PTP4A3/PRL-3) promotes the aggressiveness of human uveal melanoma through dephosphorylation of CRMP2.
Duciel L; Anezo O; Mandal K; Laurent C; Planque N; Coquelle FM; Gentien D; Manneville JB; Saule S
Sci Rep; 2019 Feb; 9(1):2990. PubMed ID: 30816227
[TBL] [Abstract][Full Text] [Related]
14. Structural and Functional Analyses of an Allosteric EYA2 Phosphatase Inhibitor That Has On-Target Effects in Human Lung Cancer Cells.
Anantharajan J; Zhou H; Zhang L; Hotz T; Vincent MY; Blevins MA; Jansson AE; Kuan JWL; Ng EY; Yeo YK; Baburajendran N; Lin G; Hung AW; Joy J; Patnaik S; Marugan J; Rudra P; Ghosh D; Hill J; Keller TH; Zhao R; Ford HL; Kang C
Mol Cancer Ther; 2019 Sep; 18(9):1484-1496. PubMed ID: 31285279
[TBL] [Abstract][Full Text] [Related]
15. Allosteric inhibitors of the Eya2 phosphatase are selective and inhibit Eya2-mediated cell migration.
Krueger AB; Drasin DJ; Lea WA; Patrick AN; Patnaik S; Backos DS; Matheson CJ; Hu X; Barnaeva E; Holliday MJ; Blevins MA; Robin TP; Eisenmesser EZ; Ferrer M; Simeonov A; Southall N; Reigan P; Marugan J; Ford HL; Zhao R
J Biol Chem; 2014 Jun; 289(23):16349-61. PubMed ID: 24755226
[TBL] [Abstract][Full Text] [Related]
16. The dual inhibition against the activity and expression of tyrosine phosphatase PRL-3 from a rhodanine derivative.
Lin L; Lu L; Yuan C; Wang A; Zhu M; Fu X; Xing S
Bioorg Med Chem Lett; 2021 Jun; 41():127981. PubMed ID: 33766767
[TBL] [Abstract][Full Text] [Related]
17. Effect of protein-tyrosine phosphatase 4A3 by small interfering RNA on the proliferation of lung cancer.
Lian YX; Chen R; Xu YH; Peng CL; Hu HC
Gene; 2012 Dec; 511(2):169-76. PubMed ID: 23036709
[TBL] [Abstract][Full Text] [Related]
18. Correction to "Structure of the Complex of an Iminopyridinedione Protein Tyrosine Phosphatase 4A3 Phosphatase Inhibitor with Human Serum Albumin".
Mol Pharmacol; 2020 Dec; 98(6):781. PubMed ID: 33203716
[No Abstract] [Full Text] [Related]
19. Discovery and SAR of a novel selective and orally bioavailable nonpeptide classical competitive inhibitor class of protein-tyrosine phosphatase 1B.
Andersen HS; Olsen OH; Iversen LF; Sørensen AL; Mortensen SB; Christensen MS; Branner S; Hansen TK; Lau JF; Jeppesen L; Moran EJ; Su J; Bakir F; Judge L; Shahbaz M; Collins T; Vo T; Newman MJ; Ripka WC; Møller NP
J Med Chem; 2002 Sep; 45(20):4443-59. PubMed ID: 12238924
[TBL] [Abstract][Full Text] [Related]
20. In silico structure-based design of a potent and selective small peptide inhibitor of protein tyrosine phosphatase 1B, a novel therapeutic target for obesity and type 2 diabetes mellitus: a computer modeling approach.
Rao GS; Ramachandran MV; Bajaj JS
J Biomol Struct Dyn; 2006 Feb; 23(4):377-84. PubMed ID: 16363874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
